TrialPath
Recruiting

SEquential Treatment of PSoriasis With Biologics

NCT07187817 · Royal United Hospitals Bath NHS Foundation Trust
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

About this study
STEPS is a retrospective observational cohort study, which will evaluate previously obtained data that had been collected in the process of routine Dermatology appointments. NHS Dermatology centres from around the United Kingdom will be recruited as sites and will submit data on patients with psoriasis treated with biologic drugs (1st to 10th line), from looking through their previous medical notes. All data submitted will be anonymous, as no identifying information will be included in the submissions. An online survey will be developed on the online platform RedCAP to collect and store the data. Each participant will have information submitted including demographic information like age and sex, as well as information about their psoriasis and treatments. The psoriasis scores (Psoriasis Area and Severity Index and Dermatology Life Quality Index) at baseline of each line of drug, and then at the 3 and 6 month follow up appointments for each line of drug, will be submitted. These measures will be used to determine if there was an improvement in psoriasis with each line of drug, if so what level of improvement, and to compare the response in the different lines of biologic. The hypothesis is that the response at 3 months to each line of biologic does not reduce with increasing lines of biologic after the 2nd line. As all the information to be submitted has been previously obtained in routine clinics, no additional visits or changes to any medication or monitoring will be required for any participants. The sample size calculation suggested that a minimum of 610 treatment courses (lines of biologic treatment) are needed to undertake a meaningful analysis, which equates to data on 366 patients. To account for missing data, which is inevitable with observational data, the aim is to recruit 7-8 sites, who will each submit data on 50 patients. The investigators aim for data submission to be completed within 6 months of the start of the study, and that analysis will take a further 6 months.
Eligibility criteria
Inclusion Criteria: * Diagnosis of chronic plaque psoriasis by a Dermatology consultant * Prior treatment with biologic or targeted synthetic treatment (1 to 10 lines) for psoriasis in the United Kingdom Exclusion Criteria: * Diagnosis of other forms of psoriasis for example generalised pustular psoriasis
Study design
Enrollment target: 366 participants
Age groups: adult, older_adult
Timeline
Starts: 2025-10-14
Estimated completion: 2026-08-07
Last updated: 2026-07-09
Primary outcomes
  • • PASI75 (12-16 weeks and 6 months)
Sponsor
Royal United Hospitals Bath NHS Foundation Trust · other
With: University of Bath, University of Leeds
Contacts & investigators
ContactCharlotte Gollins · contact · charlotteelizabeth.gollins@nhs.net · 01225 826192
ContactSarah Stratton · contact · sarah.stratton@nhs.net · 01225 826192
All locations (1)
Royal United Hospitals Bath NHS Foundation TrustRecruiting
Bath, Somerset, United Kingdom
SEquential Treatment of PSoriasis With Biologics · TrialPath